Date:8/17/2010

nd RMB2.37 (US$0.35) for the first half of 2010 compared with RMB2.13 (US$0.31) for the first half of 2009 on a non-GAAP basis. Second Quarter 2010 Business Highlights -- EPIAO, the Company's flagship injectable recombinant human erythropoietin ("EPO") product, demonstrated strong growth with net revenues from EPIAO in the second quarter of 2010 rising 22.9% to RMB62.8 million (US$9.3 million) compared to RMB51.1 million (US$7.5 million) in the second quarter of 2009. EPIAO accounted for 59.5% of total revenues in the second quarter of 2010, compared to 62.7% in the same period of 2009. According to the latest data from IMS Health China, EPIAO's market share in terms of value reached 43.3% in the first quarter of 2010. -- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin ("TPO") product, increased by 44.6% to RMB32.1 million (US$4.7 million) in the second quarter of 2010, compared to RMB22.2 million (US$3.3 million) in the second quarter of 2009. TPIAO accounted for 30.5% of total revenues in the second quarter of 2010 compared to 27.3% in the same period of 2009. -- Iron Sucrose sales grew 51.1% in the second quarter to RMB4.5 million (US$0.7 million), accounting for 4.2% of total revenues, compared to 3.6% in the second quarter of 2009. While still a relatively small share of total revenues, the strong growth validates our strategy of introducing new products that are complementary to our core nephrology franchise. -- Two novel research products, Feraheme, an IV iron product from AMAG Pharmaceuticals, and NuPIAO, our long-lasting second generation erythropoietin product, are waiting for approval to enter clinical phase III and phase I, respectively. 3SBio continues to work with the State Food and Drug Administration ("SFDA") to advance the regulatory approval of the three new product programs submitted in 2008. The 36,000 IU dosage formulation of EPIAO and the TPIAO label extension for the treatment of ITP are now pending manufacturing l
'/>"/>

SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference